Efficacy and Safety of Dapagliflozin in Preventing Atrial Fibrillation Recurrence After Catheter Ablation
NCT ID: NCT06740786
Last Updated: 2024-12-18
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
NA
250 participants
INTERVENTIONAL
2024-12-10
2026-05-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
control group
This group of patients will receive placebo treatment.
Dapagliflozin Treatment Group
This group of patients will receive dapagliflozin treatment after undergoing atrial fibrillation catheter ablation.
Treatment regimen: Dapagliflozin will be administered orally once daily at the recommended dose (e.g., 10 mg/day).
treatment group
Dapagliflozin will be administered orally once daily at the recommended dose (e.g., 10 mg/day).
Dapagliflozin Treatment Group
This group of patients will receive dapagliflozin treatment after undergoing atrial fibrillation catheter ablation.
Treatment regimen: Dapagliflozin will be administered orally once daily at the recommended dose (e.g., 10 mg/day).
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Dapagliflozin Treatment Group
This group of patients will receive dapagliflozin treatment after undergoing atrial fibrillation catheter ablation.
Treatment regimen: Dapagliflozin will be administered orally once daily at the recommended dose (e.g., 10 mg/day).
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
First-time Catheter Ablation: Patients undergoing their first atrial fibrillation catheter ablation.
Voluntary Participation: Patients willing to participate and sign informed consent.
Exclusion Criteria
Allergy to Dapagliflozin or Similar Drugs: History of allergic reactions to dapagliflozin or other SGLT2 inhibitors.
Other Contraindications to Dapagliflozin: Any other contraindications for dapagliflozin use.
Kidney Function: eGFR \< 45 ml/min/1.73m², with severe kidney disease.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Hefei Binhu Hospital
OTHER
The First People's Hospital of Hefei
OTHER
Second People's Hospital of Hefei City
OTHER
The Second People's Hospital of Anhui Province
OTHER
Xu Liu
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Xu Liu
Professor
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
DAPAF
Identifier Type: -
Identifier Source: org_study_id